FIELD: medicine.
SUBSTANCE: inventions group relates to the field of medicine, namely to a rapidly disintegrating oral pharmaceutical composition comprising an open matrix cellular structure carrying one or more pharmaceutically active ingredients, where the open matrix cellular structure includes 40-99% maltodextrin and 0.99-5% hyaluronic acid or its sodium salt, based on the total weight of the open matrix cellular structure and the material carried by the open matrix cellular structure, also relates to a rapidly disintegrating oral pharmaceutical composition comprising a matrix carrying one or more pharmaceutically active ingredients, the matrix disintegrating upon contact with an aqueous medium, said matrix comprising 40-99% maltodextrin and 0.99-5% hyaluronic acid or its sodium salt, based on the total weight of the matrix and the material carried by the matrix, also relates to a method for preparing a rapidly disintegrating oral pharmaceutical composition comprising sublimating a solvent from a solidified liquid preparation comprising one or more pharmaceutically active ingredients, maltodextrin and hyaluronic acid or its sodium salt in a solvent, and a method for preparing a rapidly disintegrating oral pharmaceutical composition comprising: (a) obtaining a liquid preparation comprising maltodextrin, hyaluronic acid or its sodium salt and one or more active ingredients in a solvent; (b) freezing said liquid preparation; (c) sublimating the solvent from the frozen preparation to obtain a pharmaceutical composition, wherein the pharmaceutical composition disintegrates within 30 seconds upon contact with an aqueous medium.
EFFECT: invention provides the creation of a pharmaceutical composition having a high tensile strength and demonstrating rapid disintegration in an aqueous medium.
17 cl, 5 dwg, 1 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
FAST-DISSOLVING PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2566270C2 |
FAST-DISSOLVING PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2566269C2 |
QUICK-SOLUBLE PHARMACEUTICAL COMPOSITION | 2012 |
|
RU2633640C2 |
DESMOPRESSIN MEDICINAL FORMULATION DISPERSED IN MOUTH CAVITY | 2003 |
|
RU2292903C2 |
DRUG FORM DESINTEGRATING IN ORAL CAVITY | 2008 |
|
RU2482839C2 |
LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR VAGINAL DELIVERY | 2017 |
|
RU2753864C2 |
GELATIN-FREE RAPIDLY DISPERSING MEDICINAL FORMULATION | 2000 |
|
RU2242968C2 |
SET FOR PHARMACEUTICAL COMPOSITION PREPARING | 2002 |
|
RU2279292C2 |
IMPROVED PHARMACEUTICAL COMPOSITIONS | 2019 |
|
RU2777558C2 |
PHARMACEUTICAL COMPOSITION OF NEUROPROTECTIVE ACTION FOR ORAL ADMINISTRATION BASED ON HEXAMETHYLENE AMIDE BIS-(N-MONOSUCCINYL-1-GLUTAMYL-L-LYSINE) (VERSIONS), MADE IN FORM OF A TABLET DISPERSIBLE IN THE ORAL CAVITY | 2018 |
|
RU2740754C1 |
Authors
Dates
2021-07-12—Published
2018-01-11—Filed